Horizon Discovery and Desktop Genetics collaborate on CRISPR design platform
Horizon Discovery, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has entered into a collaboration agreement with Desktop Genetics for development of a CRISPR design platform.
Horizon Discovery wins multiple business and industry awards
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, has won several major life science industry and UK business awards in Q4 2013, as well as being announced as one of the first 25 companies selected for the ‘Future Fifty’ scheme. These awards are testament to the strength of Horizon’s position as one of the leading biotech companies in…
Horizon Discovery and AstraZeneca win 'Licensing Deal of the Year' at Scrip Awards 2013
Horizon Discovery has won “Licensing Deal of the Year” at the Scrip Awards 2013, for its agreement with AstraZeneca to explore Horizon’s first-in-class kinase target program HD-001 as a means of developing novel therapies for multiple cancer types. The Scrip Awards are highly prestigious, recognising excellence in both pharma and biotech companies and those firms that support them.
Horizon Discovery CEO joins UKTI delegation to India led by David Cameron
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today reported that the company’s CEO Dr. Darrin Disley was selected to join the recent UKTI delegation to Prabodhan 2013 in Delhi, India.
Horizon Discovery ranks Number 22 in Deloitte Technology Fast 50
Horizon Discovery today announced that it ranked Number 22 in the 2013 Deloitte Technology Fast 50, a ranking of the 50 fastest-growing technology companies in the UK. Rankings are based on percentage revenue growth over five years. Horizon grew 1027% percent during this period.
David Evans steps down as Chairman of the Board for Horizon Discovery
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, today announced Mr David Evans has stepped down as Chairman of the Board. Dr Ian Gilham, who was recently appointed as a non-executive director for Horizon Discovery, will act as interim Chairman. Horizon is actively seeking a high profile non-executive with international standing to act…
Horizon Discovery selected for Tech City UK’s ‘Future Fifty’ programme
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, today announced it has been accepted onto Tech City UK’s ‘Future Fifty’ programme.
Horizon Discovery receives share of €5.75M ($7.8M) EU FP7 grant
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, today announced it has received a share of an EU FP7 Grant totaling €5.75M ($7.8M), awarded to a consortium of research institutions and companies for the ‘CV genes-at-target’ project. The grant will fund projects investigating genomic variants affecting coronary artery disease and stroke…
Horizon Discovery and Blueprint Medicines enter oncology research service agreement
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced it has signed a research service agreement with Blueprint Medicines Corp., a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets.
Horizon Discovery licenses CRISPR gene editing technology from Harvard University
Horizon Discovery, a leading provider of research tools to support translational genomics research and the development of personalised medicines, announced it has entered into a non-exclusive licence agreement with Harvard University to access intellectual property related to the commercialization of CRISPR gene editing technology for research use.
Horizon Discovery licenses Zinc finger nuclease gene editing technology from Sigma-Aldrich
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced it has entered into a non-exclusive license agreement with Sigma-Aldrich (Sigma) for use of their CompoZr ® zinc finger nuclease (ZFN) technology. The deal gives Horizon the commercial freedom to apply the technology alongside its proprietary rAAV technology in its gene…
Horizon Discovery strengthens Board with appointment of Dr. Ian Gilham
Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, has announced the appointment of Dr. Ian Gilham as a non-executive director.
Horizon Discovery and RIKEN GENESIS sign distribution agreement
Horizon Diagnostics (HDx), a division of Horizon Discovery and a leading provider of research tools to support the development and prescription of personalized medicines, today announced it has signed a distribution agreement with RIKEN GENESIS, to become sole distributor of HDx’s molecular reference standards in Japan.
Horizon and Hisun Pharmaceuticals partner on gene-engineered bioproduction cell line
Horizon Discovery, a leading provider of cell line genome engineering products and services, today announced it has entered into an agreement with Hisun Pharmaceuticals (Hisun) to optimize Horizon’s newly engineered CHO bioproduction cell line for commercial use. Hisun will be using Horizon’s glutamine synthetase (GS) double knock-out cell line for use in therapeutic antibody manufacturing…
Horizon Discovery announces £6.9 million Series C continuation fundraising
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced the final closing of its Series C funding round. The latest £6.9m ($10.5m) placement for ordinary shares brings to a close a cumulative total for the round of £18.2m ($29.1m) and will enable Horizon to transition from a three-year investment phase (2010-12) to an organic…
Horizon Discovery announces >$75M oncology drug discovery collaboration with AstraZeneca
Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and licence agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.
Horizon Discovery and Diatech Pharmacogenetics sign distribution agreement
Horizon Diagnostics (HDx), a division of Horizon Discovery and a leading provider of research tools to support the development and prescription of personalized medicines, today announced it has signed a distribution agreement with Diatech Pharmacogenetics srl. Diatech Pharmacogenetics becomes sole distributor of HDx’s molecular reference standards in Italy, San Marino and Vatican City.
Crown Bioscience Inc. and Horizon Discovery announce exclusive two year agreement...
Crown Bioscience Inc. and Horizon Discovery announce exclusive two year agreement to offer combined solutions for in vivo drug discovery model development
Horizon Discovery establishes new Centers of Excellence in Cambridge
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced it has established two new Centers of Excellence (CoEs) for gene editing in Cambridge, UK. The new Centers are at the Gurdon Institute, Cambridge University with Prof. Steve Jackson FRS, and the Cambridge Institute for Medical Research with Prof. David Rubinsztein.
Horizon increases precision and utility of molecular assays for cancer genotype screening
Horizon Diagnostics (HDx), a division of Horizon Discovery, a leading provider of research tools to support the development and prescription of personalized medicines, today announced it has launched its first Quantitative Multiplex DNA Reference Standard. This standard is the first of its kind and is intended for researchers assessing multiple biomarkers in a single assay, using platforms such…
Horizon Discovery establishes three new Centers of Excellence in Asia
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced it has established three new Centers of Excellence (CoEs) for gene editing in Asia.
Horizon wins 'Most Promising Company' at World Conference on Personalized Medicine
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, has been named ‘Most Promising Company’ at the Personalized Medicine World Conference 2013. Horizon was chosen from 32 shortlisted companies based on technology, historical performance of the company, and forward business plans.
Horizon Discovery and Boehringer Ingelheim enter oncology research service collaboration
Horizon Discovery Ltd, a leading provider of research tools to support the development of personalized medicines, today announced it has signed a research service collaboration agreement with Boehringer Ingelheim. The five year collaboration will support Boehringer Ingelheim’s drug discovery programmes.
Horizon Discovery launches new website
Horizon Discovery Ltd, a leading provider of research tools to support the development of personalized medicines, has launched a new, redesigned website.
Horizon Discovery and Promega launch suite of X-MAN reporter kits
Horizon Discovery Ltd., a leading provider of research tools to support the development of personalied medicines, and Promega Corporation have announced the launch of a suite of X-MAN™ Reporter Kits. These kits enable researchers, for the first time, to apply functional, cell-based assays that directly interrogate critical biological activities, at endogenous expression levels. The resulting data…